Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C
Download the MIMS Education app now!
Direct-Acting Antivirals in the Treatment of Chronic Hepatitis C
Gastroenterology And HepatologyInfectious DiseasesFamily MedicineGeneral PracticeInternal Medicine
CME Unit: 1 Point | 
1 hour | 
07 Dec 2022
Overview
About this course
Hepatitis C virus (HCV) causes chronic inflammation of the liver and can result in fatal complications, including cirrhosis and hepatocellular carcinoma. This module aims to review the guidelines surrounding HCV infection and the direct-acting antivirals (DAA) available for treatment.
Learning outcomes
Upon completion of the learning activity, the participant should be able to- Identify the different algorithms in the management of chronic HCV
- Recognize the differences in different available screening recommendations
- List the different available DAAs and their side effects
- Review the recommendations for management post-treatment with DAA
Topics covered
- The prevalence of HCV globally and locally
- Regional algorithm on management of chronic HCV
- Difference between acute vs chronic HCV
- Asia-Pacific and global screening and therapy recommendations
- Treatment options available for HCV (Antiviral therapy/DAAs)
- Recommendations for treatment monitoring
1 CME Point Available
- This module is accredited for 1 CME Point for medical practitioners enrolled in The Medical Council of Hong Kong’s Continuing Medical Education Programme for Practising Doctors who are not taking CME for Specialists.
- This module is accredited for both Hong Kong Doctors Union (HKDU) members and non-members.
- This module is accredited for 1 CME Point for fellows of the Hong Kong College of Physicians.
- Please note that this module will not earn CME credit for fellows of colleges not listed here.
- A certificate can be downloaded upon successful completion of the quiz. Please use the information on the certificate to claim your CME points.